Carregant...

Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study

BACKGROUND: In our previous study, we investigated the efficacy of ipragliflozin, a sodium-glucose cotransporter (SGLT) 2 inhibitor on diabetic nephropathy in patients with type 2 diabetes and demonstrated that ipragliflozin significantly improved diabetic nephropathy in addition to reducing HbA1c a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Med Res
Autors principals: Ito, Daisuke, Inoue, Kazuyuki, Sumita, Takashi, Hamaguchi, Keiko, Kaneko, Kimie, Yanagisawa, Morifumi, Inukai, Kouichi, Inoue, Ikuo, Noda, Mitsuhiko, Shimada, Akira
Format: Artigo
Idioma:Inglês
Publicat: Elmer Press 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089574/
https://ncbi.nlm.nih.gov/pubmed/30116437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3491w
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!